Cart is empty For patients with nonsegmental vitiligo, continued improvement in seen during a long-term extension of ruxolitinib treatment, according to study presented at the annual meeting of the American Academy of Dermatology, held from March 17 to 21 in New Orleans.
Leave A Comment